[Sulfonylureas and glinides].
Hirose
Takahisa
T
Department of Medicine, Metabolism and Endocrinology, Juntendo University School of Medicine.
D003510:Cyclohexanes / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D024821:Metabolic Syndrome / Q000188:drug therapy*; D000077715:Nateglinide; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*
D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; D000077715:Nateglinide; D010649:Phenylalanine